Objective. To identify key microRNAs (miRNAs) and their regulatory networks in prostate cancer. Methods. Four miRNA and three gene expression microarray datasets were downloaded for analysis from Gene Expression Omnibus database. The differentially expressed miRNA and genes were accessed by a GEO2R. Functional and pathway enrichment analyses were performed using the DAVID program. Protein-protein interaction (PPI) and miRNA-mRNA regulatory networks were constructed using the STRING and Cytoscape tool. Moreover, the results and clinical significance were validated in TCGA data. Results. We identified 26 significant DEMs, 633 upregulated DEGs, and 261 downregulated DEGs. Functional enrichment analysis indicated that significant DEGs were related to TGF-beta signaling pathway and TNF signaling pathway in PCa. Key DEGs such as HSPA8, PPP2R1A, CTNNB1, ADCY5, ANXA1, and COL9A2 were found as hub genes in PPI networks. TCGA data supported our results and the miRNAs were correlated with clinical stages and overall survival. Conclusions. We identified 26 miRNAs that may take part in key pathways like TGF-beta and TNF pathways in prostate cancer regulatory networks. MicroRNAs like miR-23b, miR-95, miR-143, and miR-183 can be utilized in assisting the diagnosis and prognosis of prostate cancer as biomarkers. Further experimental studies are required to validate our results.

1. Introduction

Prostate cancer (PCa) is a major cancer bothering men worldwide. With an estimated 19% new cancer incidence in men, PCa continues to hold the highest morbidity among all cancer types in the United States [1]. During the past decades, urologists have made great progress in the diagnosis and treatment of PCa [2]. Currently, the new types of biomarkers such as liquid biopsy and imaging biomarker start to make contributions to clinical decision making [3–5]. However, PCa is a heterogeneous cancer with individual disparity; therefore, genomic and molecular resources still play an important role in discriminating aggressive cases and aiding prognosis prediction [6].

MicroRNA (miRNA), also known as short noncoding RNA, is a group of single-stranded RNA molecules that act as posttranscriptional gene regulation [7]. MiRNAs are involved in many cellular biological processes such as proliferation, migration, apoptosis, invasion, and epithelial-mesenchymal transition (EMT). Accumulating evidence shows that miRNAs can functionally act as oncogene or tumor suppressors [8]. In addition, circulating miRNA can be detected without invasion like biopsy [9]. Hence, miRNAs can be applied to help diagnosis and prognosis. Multiple studies of miRNA-PCa have been performed, but they often had the disadvantages of heterogeneous design, small sample size, and less clinical information.

To the best of our knowledge, there are few studies integrating microarray datasets to access key molecules and investigate miRNA-mRNA regulatory networks. The objective of this study is to find the key miRNAs and their potential regulatory mechanisms in PCa by bioinformatic approaches.
2. Materials and Methods

2.1. Microarray Data. Three gene expression profiles (GSE55945, GSE60329, and GSE103512) and four miRNA expression profiles (GSE26367, GSE64333, GSE21036, and GSE54516) were obtained from the Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo). The profiles based on PCa cell lines or xenograft models were excluded; thus, only PCa patients and healthy controls were preserved in this study. Every included dataset contains more than ten PCa samples and normal prostate tissues. The characteristics of these profiles are shown in Table 1.

2.2. Data Processing. We performed the comparison on the two groups of samples (PCa versus normal prostate tissues) in each GEO dataset to identify differentially expressed genes (DEGs) and differentially expressed miRNAs (DEMs). The comparison was launched by a limma R package based online program, GEO2R (http://www.ncbi.nlm.nih.gov/geo/geo2r/). The adjusted P value (adj. P value) from the Benjamini–Hochberg method could correct the false positive results. So we chose the “adj. P value<0.05” and “|logFC|>1” as a primary cut-off criteria to interpret the results. Among the DEMs from the four datasets, only those appeared in two or more datasets were considered as the significant DEMs.

2.3. Identification of miRNA Targets. The MiRWalk 2.0 database provides a large collection of predicted and experimentally verified miRNAs-targets binding sites information [10]. We downloaded the significant DEMs-mRNA intersection data from the MiRWalk 2.0-validated-target miRNA-gene retrieval system, which contains all literature-reported miRNA-target genes. However, the validated target genes were from various diseases models, so the expression of those genes in PCa might not be consistent with other diseases. We subsequently selected the genes from the intersection between the significant DEMs-mRNA intersection data and the DEGs from the three GEO datasets. These genes were defined as the significant DEMs.

2.4. Functional Enrichment Analysis. The Database for Annotation, Visualization, and Integrated Discovery (DAVID) is an online program that offers functional annotation of enormous quantity of genes derived from various genomic resources [11]. We used the DAVID database to perform Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis on significant DEGs. The species was limited to Homo sapiens and the “P value <0.05” was considered statistically significant.

2.5. Interaction and Regulatory Network Establishment. Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) was used to construct protein-protein interaction (PPI) network. The STRING database collects and predicts interaction information from genomic context predictions, high-throughput lab experiments, coexpression, automated text-mining, and previous knowledge in databases [12]. To access more objective and reliable results, we restricted the sources as high-throughput lab experiments and previous knowledge in databases. In addition, the minimum interaction score was set at high confidence (0.700).

The miRTarBase (http://miRTarBase.mbc.nctu.edu.tw/) is a miRNA intersection database based on validation from experiments such as assay, microarray, sequencing quantitative PCR, and western blot. The miRanda algorithm from the “microRNA.org-Targets and Expression” was freely available and can be applied to the whole genome sequences using identified miRNA sequences [13]. The two programs above were used to predict target miRNAs of the significant DEMs. When two miRNAs shared a common target mRNA; they might exist in a similar regulatory pathway. The miRNA-mRNA regulatory network was visualized by Cytoscape 3.6.0 [14].

2.6. Validation and Survival Analysis. The Cancer Genome Atlas (TCGA) database provides abundant clinical information from huge sample size. Therefore, the dataset “TCGA-PRAD” was used to find if the significant DEMs were correlated with survival outcome. The dataset “TCGA-PRAD” consists of 498 PCa samples with 52 normal prostate samples. Among the 494 clinical outcome events available, 484 patients were living and 10 were dead when the follow-up ended. We examined the significant DEMs expression, relationship with PCa stages, and survival. The “t-test” was applied to check expression level, while the chi-square test was used on different stages. The Kaplan-Meier plots were constructed by OncomiR [15]. The “P value <0.05” was considered statistically significant.

3. Results

3.1. DEGs/DEMs Identification. After being compared with normal prostate tissues, the results of GEO2R analysis
showed that there were totally 2333 upregulated DEGs (Figure 1(b)), 1188 downregulated DEGs (Figure 1(c)), and 193 DEMs (Figure 1(a)) in PCa samples. Among them, 26 DEMs appeared in the results of two datasets at least, so they were identified as significant DEMs. Additionally, miR-183 was the only DEM in all four datasets simultaneously. The following DEMs were found in three datasets: miR-96, miR-375, miR-143, miR-1, and miR-145.

By MiRWalk 2.0-validated-target miRNA-gene retrieval system, we got 4475 candidate genes of the 26 significant DEMs. The intersection number of these candidate genes and the upregulated DEGs was 633. For the downregulated DEGs, 261 genes were intersected with the 4475 candidate genes. Therefore, the 633 upregulated and the 261 downregulated genes were identified as the final sets of significant DEGs.

3.2. GO and Pathway Enrichment. The GO ontology contains three terms: cellular component (CC), molecular function (MF), and biological process (BP). The results demonstrated that the most significant GO terms for upregulated significant DEGs were “protein binding (MF)”, “nucleoplasm (CC)”, and “poly(A) RNA binding (MF)”, whereas for the downregulated significant DEGs, “extracellular matrix (CC)”, “cell surface (CC)”, and “protein binding (MF)” turned to be important (Table 2).

Furthermore, the KEGG pathway analysis indicated that “prostate cancer”, “TGF-beta signaling pathway”, “TNF signaling pathway”, and “focal adhesion” pathways played an essential role in PCa pathogenesis (Table 2).

3.3. PPI Network. PPI networks were established separately by significant upregulated DEGs (Figure 2(a)) and significant downregulated DEGs (Figure 2(b)). In respect of the former, 294 nodes and 926 edges in total constituted the PPI network. In regard to the latter, the network was composed of 93 nodes and 153 edges.

In a PPI network, the more edges a gene has, the more important role it plays (like a seed). We used the parameter “degree” to calculate edge counts of every single gene in a PPI network. The top 5% degree genes were listed in Table 3, which were assessed as hub genes.
### Table 2: Results of top 10 gene ontology (GO) categories and the top 5 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis.

| Category         | Term          | Description                                      | Gene counts | P-value |
|------------------|---------------|--------------------------------------------------|-------------|---------|
| **Up-regulated gene** |               |                                                  |             |         |
| GO:0005515      | MF            | protein binding                                  | 416         | 1.40E-20|
| GO:0005654      | CC            | nucleoplasm                                      | 164         | 5.20E-14|
| GO:0044822      | MF            | poly(A) RNA binding                              | 88          | 1.80E-12|
| GO:0005829      | CC            | cytosol                                          | 180         | 3.00E-12|
| GO:0005913      | CC            | cell-cell adherens junction                      | 40          | 3.20E-12|
| GO:0098641      | MF            | cadherin binding involved in cell-cell adhesion  | 37          | 4.00E-11|
| GO:0070062      | CC            | extracellular exosome                            | 153         | 2.50E-10|
| GO:0005634      | CC            | nucleus                                          | 252         | 3.10E-10|
| GO:0098609      | BP            | cell-cell adhesion                               | 33          | 1.40E-09|
| GO:0005737      | CC            | cytoplasm                                        | 237         | 1.90E-08|
| hsa05215        | KEGG          | Prostate cancer                                  | 14          | 4.10E-05|
| hsa04350        | KEGG          | TGF-beta signaling pathway                       | 11          | 1.80E-03|
| hsa05202        | KEGG          | Transcriptional misregulation in cancer          | 16          | 2.80E-03|
| hsa05210        | KEGG          | Colorectal cancer                                | 9           | 3.00E-03|
| hsa04910        | KEGG          | Insulin signaling pathway                         | 14          | 3.30E-03|
| **Down-regulated gene** |               |                                                  |             |         |
| GO:0031012      | CC            | extracellular matrix                             | 23          | 2.20E-10|
| GO:0009986      | CC            | cell surface                                     | 28          | 1.30E-08|
| GO:0005515      | MF            | protein binding                                  | 170         | 1.00E-07|
| GO:0005925      | CC            | focal adhesion                                   | 22          | 1.70E-07|
| GO:0030198      | BP            | extracellular matrix organization                | 16          | 2.30E-07|
| GO:0005578      | CC            | proteinaceous extracellular matrix               | 17          | 1.30E-06|
| GO:0007155      | BP            | cell adhesion                                    | 22          | 4.80E-06|
| GO:0045944      | BP            | positive regulation of transcription from RNA polymerase II promoter | 34 | 8.30E-06|
| GO:0008201      | MF            | heparin binding                                  | 12          | 2.40E-05|
| GO:0030574      | BP            | collagen catalytic process                       | 8           | 4.30E-05|
| hsa04668        | KEGG          | TNF signaling pathway                            | 12          | 3.30E-06|
| hsa04510        | KEGG          | Focal adhesion                                   | 16          | 4.80E-06|
| hsa05205        | KEGG          | Proteoglycans in cancer                          | 15          | 1.60E-05|
| hsa05144        | KEGG          | Malaria                                          | 7           | 2.50E-04|
| hsa04064        | KEGG          | NF-kappa B signaling pathway                     | 8           | 1.00E-03|

BP: biological process; CC: cellular component; MF: molecular function

3.4. **MiRNA-mRNA Regulatory Network.** As demonstrated in Figure 3, the target genes were predicted by miRanda and miRTarbase, among which two or more miRNA might target the same mRNA. For instance, miR-1, miR-145, miR-143, miR-205, and miR-31 all had interactions with cyclin dependent kinase 4 (CDK4). There were 21 mRNA nodes which might interact with more than two miRNAs.

3.5. **Validation and Kaplan-Meier Curves.** After comparing the expression level of miRNAs in the TCGA dataset, we found that 23 among the 26 significant DEMs were in accordance with the results in GEO databases. However, the expression of miR-1, miR-519b, and miR-572 was not significantly different between PCa samples and normal control prostate tissues. The relationship of miRNAs between the clinical TNM stages was also tested in the TCGA dataset using chi-square analysis. The results of the significant DEMs were shown in Table 4.

We subsequently drew Kaplan-Meier plots (Figure 4) based on the TCGA survival data. Four significant DEMs, miR-95, miR-23b, miR-143, and miR-183 were found related to overall survival (OS) in PCa patients. The higher expression of these miRNAs meant poor OS in patients with PCa.

4. **Discussion**

In the present study, we identified 26 significant DEMs, 633 upregulated DEGs, and 261 downregulated DEGs. The results of functional enrichment analysis indicated that the significant DEGs were related to TGF-beta signaling pathway and TNF signaling pathway in PCa. The key DEGs such as HSPA8, PPP2R1A, CTNNB1, ADCY5, ANXA1, and COL9A2 were found as hub genes in PPI networks. Importantly, some of the DEMs were validated and found correlated with tumor stages and survival, which meant the miRNAs could not only
Figure 2: PPI network of DEGs. (a) Upregulated DEGs and (b) downregulated DEGs.
Table 3: The top 5% hub genes in the protein-protein interaction (PPI) networks.

| Entrez Gene ID | Gene symbol | Full gene name                          | Degree |
|----------------|-------------|----------------------------------------|--------|
| Up-regulated gene |
| 3312           | HSPA8       | heat shock protein family A (Hsp70) member 8 | 40     |
| 5518           | PPP2R1A     | protein phosphatase 2 scaffold subunit Aalpha | 32     |
| 1499           | CTNNB1      | catenin beta 1                          | 25     |
| 8334           | HIST1H2AC   | histone cluster 1 H2A family member c   | 24     |
| 10921          | RNPS1       | RNA binding protein with serine rich domain 1 | 23     |
| 85236          | HIST1H2BK   | histone cluster 1 H2B family member k   | 22     |
| 8970           | HIST1H2BJ   | histone cluster 1 H2B family member j   | 22     |
| 5878           | RAB5C       | RAB5C, member RAS oncogene family       | 22     |
| 595            | CCND1       | cyclin D1                               | 21     |
| 8301           | PICALM      | phosphatidylinositol binding clathrin assembly protein | 21     |
| 25977          | NECAP1      | NECAP endocytosis associated 1          | 21     |
| 51429          | SNX9        | sorting nexin 9                        | 21     |
| 8349           | HIST2H2BE   | histone cluster 2 H2B family member e   | 20     |
| 1026           | CDKNI1A     | cyclin dependent kinase inhibitor 1A    | 20     |
| Down-regulated gene |
| 111            | ADCY5       | adenylyl cyclase 5                      | 12     |
| 301            | ANXA1       | annexin A1                             | 11     |
| 1298           | COL9A2      | collagen type IX alpha 2 chain          | 10     |
| 1277           | COL1A1      | collagen type I alpha 1 chain           | 9      |

Table 4: Results of the significant DEMs expression validation and the relationship with PCa clinical stages in TCGA data.

| MiRNA ID  | Up-regulated in | P-value (t-test) | Clinical stages          | P-value (chi-square) |
|-----------|-----------------|------------------|--------------------------|----------------------|
| hsa-miR-133a-3p | normal          | 8.93E-03          | pathologic T/N status    | 9.50e-09/ 1.32e-04   |
| hsa-miR-133b  | normal          | 9.53E-07          | pathologic T/N status    | 7.96e-07/ 8.83e-05   |
| hsa-miR-143-3p | normal          | 1.10E-13          | clinical T/M status      | 5.04e-03/3.70e-03    |
| hsa-miR-145-3p | normal          | 1.65E-07          | pathologic T/N status    | 7.86e-07/ 1.49e-04   |
| hsa-miR-148a-3p | tumor           | 7.67E-13          | -                        | -                    |
| hsa-miR-148a-5p | tumor           | 4.66E-10          | pathologic T status      | 2.10e-03             |
| hsa-miR-153-3p | tumor           | 4.12E-20          | pathologic T status      | 4.30e-02             |
| hsa-miR-182-5p | tumor           | 7.57E-16          | clinical T/M status      | 4.23e-03/ 3.06e-02   |
| hsa-miR-183-5p | tumor           | 1.56E-15          | pathologic T status/Clinical M Status | 7.85e-03/ 1.25e-03  |
| hsa-miR-187-3p | normal          | 1.52E-10          | -                        | -                    |
| hsa-miR-204-5p | normal          | 2.62E-06          | pathologic T/N status    | 2.44e-03/ 1.77e-02   |
| hsa-miR-205-5p | normal          | 1.39E-02          | pathologic T status      | 1.17e-02             |
| hsa-miR-221-3p | normal          | 6.18E-10          | pathologic T/N status    | 4.10e-07/ 3.70e-04   |
| hsa-miR-221-5p | normal          | 1.44E-05          | pathologic T/N status    | 5.69e-03/ 5.19e-03   |
| hsa-miR-222-3p | normal          | 5.76E-07          | pathologic T/N status    | 4.71e-09/ 2.77e-04   |
| hsa-miR-222-5p | normal          | 1.17E-04          | pathologic T status/Clinical M Status | 1.37e-03/ 4.81e-02  |
| hsa-miR-224-5p | normal          | 2.31E-02          | pathologic T status      | 5.62e-04             |
| hsa-miR-23b-3p | normal          | 8.14E-03          | pathologic T/N status    | 9.60e-03/ 3.24e-02   |
| hsa-miR-31-3p  | normal          | 3.97E-02          | -                        | -                    |
| hsa-miR-32-3p  | tumor           | 2.96E-03          | pathologic T/N status    | 3.29e-03/ 3.81e-02   |
| hsa-miR-363-3p | tumor           | 1.18E-08          | pathologic N status      | 2.92e-02             |
| hsa-miR-375    | tumor           | 8.87E-13          | -                        | -                    |
| hsa-miR-550a-5p | tumor           | 1.08E-04          | -                        | -                    |
| hsa-miR-7-5p   | tumor           | 1.70E-03          | pathologic T/N status    | 4.28e-02/ 2.03e-03   |
| hsa-miR-95-3p  | tumor           | 8.29E-06          | pathologic T status      | 7.17e-03             |
| hsa-miR-96-5p  | tumor           | 1.65E-15          | pathologic N status/Clinical M Status | 4.72e-02/ 5.81e-03  |
regulate cellular process but also be of high value in clinical practice.

In fact, prostate cancer shares a plenty of pathways with other cancers such as TNF, TGF-beta pathways. Some unique signal pathways like the androgen receptor (AR) and transmembrane protease serine 2 (TMPRSS2) relevant pathways also play a crucial role in PCa. In these complicated processes, miRNAs nearly take part in all key cellular pathways considering that one miRNA can interact with many mRNAs and one mRNA can also interact with many miRNAs. Interestingly, miR-183 was the only one significant DEM expressed in all four different datasets. We assumed that ethnics and sample size may cause this heterogeneity. In accordance with our result, miR-183 has been testified overexpression in PCa serum, tissue, and cell line [16]. Ueno reported that miR-183 could target Dkk-3 and SAMAD4 and has an oncogenic biological behavior [17]. Due to the paralogous property of miR-183, miR-96, and miR-182, these three miRNAs have been studied as miR-183 cluster, which could regulate zinc levels and carcinogenic pathways in prostate cells [18]. MiR-96 was also reported enhancing PCa cell proliferation through FOXO1 [19], which could be speculated in the PPI network (Figure 2(a)). Except for the previously reported miRNAs, there are also some miRNAs not reported in PCa before like miR-95. We found that higher miR-95 expression indicated poor survival based on 494 patients in TCGA. However, we do not know if miR-95 is related to the survival of patients from other regions or countries. The mechanisms and in-depth pathways of miR-95 should also be investigated by experiments in the future.

By constructing the PPI network, we can recognize the key genes that miRNAs may interact with. Since the genes were filtered by the 26 significant DEMs potential targets, there were still 633 upregulated and 261 downregulated. Therefore, when it comes to all the 197 DEMs, the enormous and complicated miRNA-mRNA regulatory network can be imaginable. The hub genes of a network are always important like “seeds”, which connect different signal pathways. In the present study, we identified several hub genes. The regulating mechanisms HSPA8 were reported in malignancies like glioblastoma and myeloid leukaemia [20, 21]. The PPP2R1A mutation in uterine cancer was reported...
acting through a dominant-negative mechanism to promote cancer cell growth [22]. Besides, emerging evidence points out that the histone cluster is contributed to various kinds of cancers [23]. As a phospholipid-dependent, membrane-binding protein, the ANXA1 upregulation can enhance drug-resistance of PCa therapy [24]. In our predicted miRNA-mRNA network, the key mRNAs like CDKN1A,B,C and CDK4 are cell-cycle related modulators [25]. To sum up, the miRNA regulatory network may provide potential targets for new drug development and treatment. By exploiting the bioinformatic analysis on miRNAs and regulatory pathways, we can discover important and novel potential targets in the tumor-genesis, diagnosis, prognosis, and key mechanisms in different cancers such as lung cancer [26], gastric cancer [27], colorectal cancer [28], and thyroid cancer [29].

Although this study firstly investigated miRNAs’ regulatory role in PCa by integrating multiple microarray datasets, we still need to clarify some limitations. Firstly, the stages and aggressiveness of PCa were not restricted. We only researched the PCa versus normal prostate. Key miRNAs and genes in different periods like metastatic castration-resistant PCa call for deeper exploration. Secondly, the source of microarray is only tissues. Body fluid like serum, urine, and prostatic fluid may contain circulating miRNAs, which are more likely to be accepted for clinical application. Thirdly, though we validated our results in TCGA data, the microarray results

**Figure 4:** The Kaplan-Meier plots of patients from TCGA data.
were not validated by experiments like qRT-PCR, functional experiments in vitro. Further studies are needed to validate our results by experiments on large samples.

5. Conclusions

We identified 26 miRNAs that may take part in key pathways like TGF-beta, TNF pathways in prostate cancer regulatory networks. MicroRNAs like miR-23b, miR-95, miR-143, and miR-183 can be utilized in assisting the diagnosis and prognosis of prostate cancer as biomarkers. Further experimental studies are required to validate our results.

Data Availability

All raw data in this article can be obtained by emailing the corresponding author.

Conflicts of Interest

All authors have no conflicts of interest.

References

[1] R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, CA: A Cancer Journal for Clinicians, vol. 68, no. 1, pp. 7–30, 2018.
[2] C. E. Barbieri, A. M. Chinnaiyan, S. P. Lerner, C. Swanton, and M. A. Rubin, "The emergence of precision urologic oncology: a collaborative review on biomarker-driven therapeutics," European Urology, vol. 71, no. 2, pp. 237–246, 2017.
[3] A. Kretschmer and D. Tilki, "Biomarkers in prostate cancer – Current clinical utility and future perspectives," Critical Review in Oncology/Hematology, vol. 120, pp. 180–193, 2017.
[4] D. Li, H. Lv, X. Hao, Y. Dong, H. Dai, and Y. Song, "Prognostic value of bone scan index as an imaging biomarker in metastatic prostate cancer: A meta-analysis," Oncotarget, vol. 8, no. 48, pp. 84449–84458, 2017.
[5] D. Y. Li, X. Y. Hao, T. M. Ma, H. X. Dai, and Y. S. Song, "The prognostic value of platelet-to-lymphocyte ratio in urological cancers: a meta-analysis," Scientific Reports, vol. 7, no. 1, Article ID 15387, 2017.
[6] V. Cucchiaro, M. R. Cooperberg, M. Dall’Era et al., "Genomic Markers in Prostate Cancer Decision Making," European Urology, 2017.
[7] B. L. Jackson, A. Grabowska, and H. L. Ratan, "MicroRNA in prostate cancer: functional importance and potential as circulating biomarkers," BMC Cancer, vol. 14, p. 930, 2014.
[8] T. Huang, A. Alvarez, B. Hu, and S.-Y. Cheng, "Noncoding RNAs in cancer and cancer stem cells," Chinese Journal of Cancer, vol. 32, no. II, pp. 582–593, 2013.
[9] R. S. Liu, E. Olkhov-Mitsel, R. Jeyapala et al., "Assessment of serum microRNA biomarkers to predict reclassification of prostate cancer in patients on active surveillance," The Journal of Urology, vol. 199, no. 6, pp. 1475–1481, 2017.
[10] H. Dweep and N. Gretz, "MiRWalk2.0: a comprehensive atlas of microRNA-target interactions," Nature Methods, vol. 12, no. 8, p. 697, 2015.
[11] D. W. Huang, B. T. Sherman, and R. A. Lempicki, "Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources," Nature Protocols, vol. 4, no. 1, pp. 44–57, 2009.
[12] D. Szklarczyk, J. H. Morris, H. Cook et al., "The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible," Nucleic Acids Research, vol. 45, no. D1, pp. D362–D368, 2017.
[13] D. Betel, A. Koppal, P. Agius, C. Sander, and C. Leslie, "Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites," Genome Biology, vol. 11, no. 8, p. R90, 2010.
[14] P. Shannon, A. Markiel, O. Ozier et al., "Cytoscape: a software Environment for integrated models of biomolecular interaction networks," Genome Research, vol. 13, no. II, pp. 2498–2504, 2003.
[15] N. W. Wong, Y. Chen, S. Chen, X. Wang, and A. Valenciano, "OncomiR: an online resource for exploring pan-cancer microRNA dysregulation," Bioinformatics, vol. 34, no. 4, pp. 713–715, 2018.
[16] O. Larne, P. Ostling, B. S. Haflidadottir, Z. Hagman, A. Aakula, P. Kohonen et al., "miR-183 in prostate cancer cells positively regulates synthesis and serum levels of prostate-specific antigen," European Urology, vol. 68, no. 4, pp. 581–588, 2015.
[17] K. Ueno, H. Hirata, Y. Shahrzadi et al., "MicroRNA-183 is an oncogene targeting DKK-3 and SMAD4 in prostate cancer," British Journal of Cancer, vol. 108, no. 8, pp. 1659–1667, 2013.
[18] S. Dambal, B. Baumann, T. McCray et al., "The miR-183 family cluster alters zinc homeostasis in benign prostate cells, organoids and prostate cancer xenografts," Scientific Reports, vol. 7, article no. 7704, no. 1, 2017.
[19] J.-J. Yu, Y.-X. Wu, F.-J. Zhao, and S.-J. Xia, "MiR-96 promotes cell proliferation and clonogenicity by down-regulating of FOXO1 in prostate cancer cells," Medical Oncology, vol. 31, no. 4, article no. 910, 2014.
[20] E. S. Jose-Eneriz, J. Roman-Gomez, L. Cordeu, E. Ballestar, L. Garate, E. J. Andreu et al., "BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia," British Journal of Haematology, vol. 142, no. 4, pp. 571–582, 2008.
[21] Y. Matsuda, T. Ishiwata, H. Yoshimura, M. Hagio, and T. Arai, "Inhibition of nestin suppresses stem cell phenotype of glioblastomas through the alteration of post-translational modification of heat shock protein HSPA8/HSC71," Cancer Letters, vol. 357, no. 2, pp. 602–611, 2015.
[22] D. Haesen, L. A. Asbagh, R. Derua et al., "Recurrent PPP2R1A mutations in uterine cancer act through a dominant-negative mechanism to promote malignant cell growth," Cancer Research, vol. 76, no. 19, pp. 5719–5731, 2016.
[23] C. Rabadasso, D. Hasson, K. Ratnakumar, C.-Y. Chung, L. F. Duarte, and E. Bernstein, "Histone variants: Emerging players in cancer biology," Cellular and Molecular Life Sciences, vol. 71, no. 3, pp. 379–404, 2014.
[24] C. Guo, S. Liu, and M.-Z. Sun, "Potential role of Anxa1 in prostate cancer - Current clinical utility and future perspectives," Critical Review in Oncology/Hematology, vol. 120, pp. 180–193, 2017.
[25] B. L. Jackson, A. Grabowska, and H. L. Ratan, "MicroRNA in prostate cancer: functional importance and potential as circulating biomarkers," BMC Cancer, vol. 14, p. 930, 2014.
[26] T. Huang, A. Alvarez, B. Hu, and S.-Y. Cheng, "Noncoding RNAs in cancer and cancer stem cells," Chinese Journal of Cancer, vol. 32, no. II, pp. 582–593, 2013.
[27] R. S. Liu, E. Olkhov-Mitsel, R. Jeyapala et al., "Assessment of serum microRNA biomarkers to predict reclassification of prostate cancer in patients on active surveillance," The Journal of Urology, vol. 199, no. 6, pp. 1475–1481, 2017.
[28] H. Dweep and N. Gretz, "MiRWalk2.0: a comprehensive atlas of microRNA-target interactions," Nature Methods, vol. 12, no. 8, p. 697, 2015.
[27] Y. Huang, J. Zhu, W. Li et al., "Serum microRNA panel excavated by machine learning as a potential biomarker for the detection of gastric cancer," Oncology Reports, vol. 39, pp. 1338–1346, 2018.

[28] P. Xu, J. Wang, B. Sun, and Z. Xiao, "Integrated analysis of miRNA and mRNA expression data identifies multiple miRNAs regulatory networks for the tumorigenesis of colorectal cancer," Gene, vol. 659, pp. 44–51, 2018.

[29] J. Tang, D. Kong, Q. Cui et al., "Bioinformatic analysis and identification of potential prognostic microRNAs and mRNAs in thyroid cancer," PeerJ, vol. 6, p. e4674, 2018.